{"id":"engerix-b-vaccine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site soreness or swelling"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Engerix-B is a recombinant hepatitis B vaccine containing hepatitis B surface antigen (HBsAg) produced in yeast cells. When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (anti-HBs) and memory B cells. This immune response provides long-term protection against hepatitis B virus infection and disease.","oneSentence":"Engerix-B stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:42:18.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in infants, children, and adults"},{"name":"Post-exposure prophylaxis for hepatitis B"}]},"trialDetails":[{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT04193189","phase":"PHASE3","title":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-14","conditions":"HIV Infection, Hepatitis B","enrollment":638},{"nctId":"NCT05482295","phase":"PHASE3","title":"Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-09","conditions":"Vaccine Reaction, Vaccine Adverse Reaction","enrollment":540},{"nctId":"NCT04970836","phase":"NA","title":"The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-08-01","conditions":"Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine","enrollment":240},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06515938","phase":"NA","title":"Study on New Strategies for Hepatitis B Virus Immunization","status":"COMPLETED","sponsor":"Wu Jiang","startDate":"2013-01-01","conditions":"Vaccine Reaction","enrollment":1169},{"nctId":"NCT04456504","phase":"PHASE4","title":"HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-09-15","conditions":"Healthcare Worker, Hepatitis B Vaccine, Nonresponder","enrollment":49},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT01311674","phase":"PHASE3","title":"Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)","status":"TERMINATED","sponsor":"Emergent BioSolutions","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT02434848","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-07-23","conditions":"HIV, Communicable Diseases, Hepatitis B","enrollment":13},{"nctId":"NCT01251276","phase":"PHASE3","title":"Hepatitis B Challenge Dose in Adults (V232-059-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-30","conditions":"Hepatitis B","enrollment":204},{"nctId":"NCT04531098","phase":"PHASE3","title":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2006-03-02","conditions":"Hepatitis B","enrollment":402},{"nctId":"NCT04209400","phase":"PHASE3","title":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2014-04-18","conditions":"Hepatitis B","enrollment":100},{"nctId":"NCT04072211","phase":"PHASE4","title":"Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-11-25","conditions":"Hepatitis B Virus, Health Care Associated Infection","enrollment":641},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03627507","phase":"PHASE2, PHASE3","title":"Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-29","conditions":"Hepatitis B Infection","enrollment":158},{"nctId":"NCT02985450","phase":"","title":"A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-08","conditions":"Non-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction","enrollment":82},{"nctId":"NCT00985426","phase":"PHASE3","title":"Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":521},{"nctId":"NCT04870021","phase":"PHASE4","title":"Hepatitis B Birth Dose for Newborns","status":"COMPLETED","sponsor":"Quaid-e-Azam University","startDate":"2015-03-15","conditions":"Hepatitis B, Immunization; Infection","enrollment":218},{"nctId":"NCT03408730","phase":"PHASE3","title":"Lot-to-lot Consistency of Sci-B-Vac™ in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-14","conditions":"Hepatitis B Vaccines","enrollment":2838},{"nctId":"NCT01311024","phase":"","title":"Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage","status":"COMPLETED","sponsor":"Arto Palmu","startDate":"2011-04","conditions":"Pneumococcal Infections","enrollment":2341},{"nctId":"NCT03567382","phase":"PHASE4","title":"Arresting Vertical Transmission of Hepatitis B Virus","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-09-24","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":179},{"nctId":"NCT00839254","phase":"PHASE3","title":"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-18","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":6181},{"nctId":"NCT00861380","phase":"PHASE3","title":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":41188},{"nctId":"NCT03083158","phase":"PHASE4","title":"Immunity to Hepatitis B Vaccine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-03-06","conditions":"Hepatitis B, Immunization; Infection","enrollment":16},{"nctId":"NCT00289185","phase":"PHASE2","title":"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-27","conditions":"Malaria, Malaria Vaccines","enrollment":340},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT03393754","phase":"PHASE3","title":"Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-13","conditions":"Hepatitis B Vaccines","enrollment":1607},{"nctId":"NCT03854630","phase":"PHASE4","title":"Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-09-06","conditions":"Viral Hepatitis B, Immunization; Infection, HIV Infections","enrollment":575},{"nctId":"NCT01531075","phase":"NA","title":"Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2012-04","conditions":"Inflammatory Bowel Disease","enrollment":91},{"nctId":"NCT04326803","phase":"PHASE4","title":"Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-06-01","conditions":"Hepatitis B","enrollment":200},{"nctId":"NCT02798952","phase":"PHASE4","title":"A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-23","conditions":"Hepatitis B","enrollment":302},{"nctId":"NCT00637195","phase":"PHASE3","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-11","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":152},{"nctId":"NCT02901951","phase":"PHASE4","title":"Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-11","conditions":"Hepatitis B Vaccine","enrollment":106},{"nctId":"NCT02096263","phase":"PHASE3","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-16","conditions":"Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b","enrollment":585},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":"Hepatitis B, Hepatitis A","enrollment":596},{"nctId":"NCT00534638","phase":"PHASE4","title":"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-04","conditions":"Infections, Papillomavirus","enrollment":34412},{"nctId":"NCT02505009","phase":"PHASE4","title":"Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-05-01","conditions":"Chronic Hepatitis B","enrollment":116},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT00343915","phase":"PHASE3","title":"Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-21","conditions":"Hepatitis B","enrollment":267},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01282762","phase":"","title":"Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"Chronic Kidney Disease","enrollment":147},{"nctId":"NCT00435812","phase":"PHASE3","title":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-12","conditions":"Hepatitis B","enrollment":2428},{"nctId":"NCT01195246","phase":"PHASE3","title":"Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"End Stage Renal Disease","enrollment":155},{"nctId":"NCT01005407","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-02","conditions":"Healthy","enrollment":2452},{"nctId":"NCT00426712","phase":"PHASE1","title":"Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-01","conditions":"Hepatitis B","enrollment":42},{"nctId":"NCT01037114","phase":"PHASE4","title":"Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-27","conditions":"Hepatitis A, Hepatitis B","enrollment":50},{"nctId":"NCT02003703","phase":"PHASE3","title":"Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .","status":"COMPLETED","sponsor":"Universidad de Valparaiso","startDate":"2015-05","conditions":"Hepatitis B, HIV","enrollment":107},{"nctId":"NCT01777295","phase":"PHASE2","title":"Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-25","conditions":"Hepatitis B","enrollment":81},{"nctId":"NCT00309166","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-05","conditions":"Infections, Papillomavirus","enrollment":270},{"nctId":"NCT00524576","phase":"PHASE4","title":"Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-28","conditions":"Hepatitis B","enrollment":144},{"nctId":"NCT01000324","phase":"PHASE4","title":"Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-06","conditions":"Hepatitis A, Hepatitis B","enrollment":44},{"nctId":"NCT00984139","phase":"PHASE4","title":"Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Hepatitis B","enrollment":306},{"nctId":"NCT00805389","phase":"PHASE2","title":"Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12-15","conditions":"Hepatitis B","enrollment":713},{"nctId":"NCT00289744","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02-16","conditions":"Hepatitis B, Hepatitis A","enrollment":178},{"nctId":"NCT01138098","phase":"PHASE4","title":"Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-07","conditions":"Hepatitis B","enrollment":185},{"nctId":"NCT00197028","phase":"PHASE2","title":"Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08-23","conditions":"Malaria","enrollment":214},{"nctId":"NCT01847430","phase":"PHASE4","title":"Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-19","conditions":"Hepatitis B","enrollment":303},{"nctId":"NCT00684671","phase":"PHASE4","title":"Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-26","conditions":"Hepatitis A, Hepatitis B","enrollment":506},{"nctId":"NCT00652938","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-09","conditions":"Infections, Papillomavirus","enrollment":744},{"nctId":"NCT00519649","phase":"PHASE4","title":"Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-31","conditions":"Hepatitis B Vaccine","enrollment":301},{"nctId":"NCT01277042","phase":"PHASE3","title":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Papillomavirus","enrollment":1212},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT00814489","phase":"PHASE1","title":"Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-08","conditions":"Streptococcus Pneumoniae, Haemophilus Influenzae","enrollment":40},{"nctId":"NCT01627340","phase":"PHASE4","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-24","conditions":"Hepatitis B","enrollment":667},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":"Haemophilus Influenzae Type b","enrollment":4003},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT01333813","phase":"PHASE4","title":"Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-26","conditions":"Hepatitis B","enrollment":300},{"nctId":"NCT02052661","phase":"PHASE4","title":"This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-18","conditions":"Hepatitis B","enrollment":301},{"nctId":"NCT03405597","phase":"PHASE3","title":"HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2017-03-30","conditions":"Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine","enrollment":97},{"nctId":"NCT00873652","phase":"","title":"Observational Study of Immune Response to Hepatitis B Childhood Booster","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT00693186","phase":"PHASE3","title":"A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Hepatitis B","enrollment":410},{"nctId":"NCT01457495","phase":"PHASE2","title":"Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib)","enrollment":312},{"nctId":"NCT00698061","phase":"PHASE3","title":"Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-11","conditions":"Hepatitis B","enrollment":145},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT01817725","phase":"PHASE1","title":"Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-03","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT00440297","phase":"PHASE3","title":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis B Virus Infection","enrollment":277},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Hepatitis B","enrollment":540},{"nctId":"NCT00393523","phase":"PHASE3","title":"Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hepatitis B","enrollment":1478},{"nctId":"NCT00106964","phase":"PHASE4","title":"Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B","enrollment":371},{"nctId":"NCT00383591","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT00603252","phase":"PHASE4","title":"Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Hepatitis B, Hepatitis A","enrollment":213},{"nctId":"NCT00142753","phase":"PHASE4","title":"Immunologic Memory (Supp. of ATN 024)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-08","conditions":"HIV Infections","enrollment":95},{"nctId":"NCT00841477","phase":"PHASE3","title":"An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2004-01","conditions":"Hepatitis B Infection, Hepatitis C Infection, HIV Infection","enrollment":1260},{"nctId":"NCT00657657","phase":"PHASE4","title":"Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04","conditions":"Hepatitis B","enrollment":29},{"nctId":"NCT00240500","phase":"PHASE4","title":"Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B","enrollment":109},{"nctId":"NCT00456625","phase":"PHASE4","title":"Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Hepatitis B","enrollment":76},{"nctId":"NCT00323622","phase":"PHASE2","title":"Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Malaria","enrollment":1737},{"nctId":"NCT00240539","phase":"PHASE4","title":"Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B","enrollment":36},{"nctId":"NCT00240526","phase":"PHASE4","title":"LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HBV vaccine","HBV"],"phase":"marketed","status":"active","brandName":"Engerix-B vaccine","genericName":"Engerix-B vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Engerix-B stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B infection in infants, children, and adults, Post-exposure prophylaxis for hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}